Skip to main content

Table 1 Characteristics of the seven patients with D. nihonkaiensis infection diagnosed in Brittany (France) from 2016 to 2018

From: Dibothriocephalus nihonkaiensis: an emerging foodborne parasite in Brittany (France)?

Patient #

Sex

Age (years)

Date of diagnosis

Putative source of infection

Putative area of infection

Clinical signs

Observed stage

Additional data

GenBank ID

1

F

27

July 2016

Japanese food

France

Abdominal pain, fatigue, diarrhea

Eggs

 

MK070861

2

M

16

September 2016

Smoked salmon or Japanese food

Probably France, possibly Sweden or Norway

None

Adult

Ate traditional smoked salmon in Norway (2004, 2007) and Sweden (2011)a

MK070860

3

F

48

August 2017

Japanese food

France

Abdominal pain, fatigue, diarrhea, loss of weight, itch

Adult

Ate raw fishes in Asia but only freshwater fishes

MK070862

4

M

30

January 2018

Japanese food

France

Abdominal pain, fatigue, diarrhea

Adult

 

MK070863

5

M

41

July 2018

Japanese food

Probably France, possibly border country

Abdominal pain, fatigue, diarrhea

Adult

Microscopic examinations of stools in October 2017 were negative for parasitesb

MK070864

6

M

42

August 2018

Undercooked salmon or Japanese food

France

Abdominal pain, fatigue, diarrhea

Adult

In early 2018: consumed undercooked salmon of unknown origin, bought at a local supermarket in Corrèze (France)

MK070865

7

F

20

September 2018

Japanese food

France

Abdominal pain, fatigue, nausea

Adult

 

MK070866

  1. aAs traditional smoked salmon is commonly made with Atlantic salmon in Northern Europe and D. nihonkaiensis is acquired through ingestion of Pacific salmon, contamination probably occurred by sushi consumption. However, the use of infected Pacific salmon by a smokery could not be completely excluded
  2. bThis patient was previously followed for pericarditis associated with 3 G/L hypereosinophilia and positive serology for anisakiosis (October 2017). After exclusion of other possible etiologies, a treatment with corticosteroids and albendazole was administered in April 2018